# Shanghai Healthcare Capital

> Shanghai Healthcare Capital is a VC fund backing Health Care. See 12 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Total investments: 12
- Last investment: Jul 2025
- Lead investor: 50%
- Last updated: Aug 2026

Shanghai Healthcare Capital is a VC fund focused on Health Care and Biotechnology. Shanghai Healthcare Capital

## Contacts

5 contacts available for Shanghai Healthcare Capital. Shizune tracks 1 team members at Shanghai Healthcare Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/shanghai-healthcare-capital?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 7 | 58% |
| Biotechnology | 6 | 50% |
| Therapeutics | 5 | 42% |
| Medical | 4 | 33% |
| Pharmaceutical | 3 | 25% |

16 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 4 | 33% |
| Series A | 3 | 25% |
| Series D | 3 | 25% |
| Seed | 1 | 8% |
| Venture - Series Unknown | 1 | 8% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 8 | 67% |
| United States | 2 | 17% |
| Israel | 1 | 8% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| David Liu | Partner | 2 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| VelaVigo | VelaVigo is a start-up company engaged in macromolecular biopharmaceuticals. | $60M | Seed | Jul 28, 2025 |  |
| Brattea | Brattea is a medical device research and development company. Brattea focuses on the development and commercialization of renal denervation products with indications in hypertension, cancer pain and diabetes. |  | Series D | Mar 25, 2024 |  |
| Geneos Therapeutics | Geneos is developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment. The company's technology is designed to identify relevant neoantigen targets from individual patient tumors to develop novel treatments for cancer, providing patients with tumor targeted immunotherapies to cure their disease. | $5M | Series A | Sep 27, 2023 |  |
| Next Generation Gene Therapeutics | Next Generation Gene Therapeutics is a healthcare company that engages in the research and development of gene therapy. Its unique propriety technology of "one target and two bullets" can provide effective treatment for a variety of genetic diseases that currently have few therapeutic methods in the world.NGGT was founded in March 2020by senior scientists and entrepreneurs in the field of gene therapy. It is committed to becoming the world's leading gene therapy company with international influence. The company has successful experience in the whole industry chain, concerning the early development of gene therapy products, the large-scale production of viral vectors, the construction of quality standards, international multi-center clinical research, and the application for the marketing of gene therapy products. | $40M | Series B | Jul 11, 2023 |  |
| ReLive Biotechnologies LTD | ReLive is a biotechnology company that develops orthopedic sports medicine and plastic and reconstructive surgery projects based on regenerative medicine and cell therapy science. | $43M | Series A | Jan 16, 2023 |  |
| ArriVent | ArriVent is dedicated to accelerating the global development of innovative biopharmaceutical products. | $155M | Series B | Dec 29, 2022 |  |
| Biomica | Biomica is a biopharmaceutical company that develops microbiome-based therapeutics to treat immune-mediated and infectious diseases, with specific focus on Immuno-Oncology and GI-related disorders. | $20M | Venture - Series Unknown | Dec 21, 2022 |  |
| Ranok Therapeutics | Ranok is a privately held, pre clinical stage bio company that is pioneering an innovative targeted protein degradation technology. | $40M | Series B | Aug 19, 2021 |  |
| Abbisko Therapeutics | Abbisko Therapeutics is a drug company dedicated to innovative drug research and development. The company is founded by a group of seasoned drug hunters with rich research and managerial experience in top pharmaceutical companies globally and in China. | $123M | Series D | Jan 07, 2021 |  |
| Immvira | Immvira was founded in Shenzhen China in May of 2015 by Prof. Bernard Roizman of University of Chicago and Prof. Grace Zhou formerly a Research Associate Professor at University of Chicago, Prof. Thomas Shenk of Princeton University, Prof. Richard Whitley of University of Alabama, Prof. Ralph Weichselbaum of University of Chicago. |  | Series B | Sep 24, 2020 |  |

10 of 12 investments shown.

## Co-investors
- [Shanghai Biomedical Industrial Equity Investment Fund](https://shizune.co/investors/profile/shanghai-biomedical-industrial-equity-investment-fund) — VC Fund, 6 deals together
- [Hankang Capital](https://shizune.co/investors/profile/hankang-capital) — VC Fund, 2 deals together
- [Lilly Asia Ventures](https://shizune.co/investors/profile/lilly-asia-ventures) — VC Fund, 2 deals together
- [Northern Light Venture Capital](https://shizune.co/investors/profile/northern-light-venture-capital) — VC Fund, 2 deals together
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 2 deals together
- [AIHC Capital](https://shizune.co/investors/profile/aihc-capital) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Shanghai Healthcare Capital invest in?

Shanghai Healthcare Capital invests primarily in Health Care, Biotechnology and Therapeutics startups, most often at Series B and Series A stage. Most of the 12 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Shanghai Healthcare Capital?

For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Shanghai Healthcare Capital?

The team at Shanghai Healthcare Capital includes David Liu (Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co